You have 9 free searches left this month | for more free features.

VEGF

Showing 1 - 25 of 3,749

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Macular Edema Due to Type 2 Diabetes Trial in Hangzhou (Anti-VEGF, subthreshold micropulse laser)

Recruiting
  • Macular Edema Due to Type 2 Diabetes Mellitus
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Feb 26, 2023

Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

Not yet recruiting
  • Lung Adenocarcinoma
  • +3 more
  • Serplulimab and Bevacizumab injection
  • (no location specified)
Dec 21, 2022

Glioblastoma Trial (Dose escalation of radiation dose beyond the therapeutic standard)

Not yet recruiting
  • Glioblastoma
  • Dose escalation of radiation dose beyond the therapeutic standard
  • (no location specified)
May 13, 2023

Following Intensive Anti-VEGF Therapy in Wet AMD

Completed
  • Age-Related Macular Degeneration
  • Budapest, Hungary
  • +1 more
Dec 28, 2022

Recurrent Brain Tumor Trial in Houston (biological, other, radiation)

Active, not recruiting
  • Recurrent Brain Neoplasm
  • Bevacizumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Diabetic Macular Edema, Pars Plana Vitrectomy, Conbercept Trial in Tianjin (Vitrectomy combined with ILM peeling, Conbercept

Not yet recruiting
  • Diabetic Macular Edema
  • +2 more
  • Vitrectomy combined with ILM peeling
  • Conbercept intravitreal injection
  • Tianjin, Tianjin, China
    Tianjin medical university eye hosipital
Feb 14, 2023

Iris Trial in Assiut (Immunohistochemistry analysis)

Not yet recruiting
  • Iris
  • Immunohistochemistry analysis
  • Assiut, Egypt
    Hassan Lotfy
Jul 29, 2022

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

Pathogenesis and Severity of COVID-19 Disease

Recruiting
  • COVID-19 Disease
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Nov 8, 2022

    Advanced Cancer Trial in Houston (Dasatinib, Bevacizumab, Paclitaxel)

    Completed
    • Advanced Cancer
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Nov 21, 2022

    Macular Degeneration Trial (Zimura, Avastin, Lucentis)

    Completed
    • Macular Degeneration
    • (no location specified)
    Oct 4, 2022

    Renal Cell Carcinoma Trial in Chapel Hill (Survey Questionnaire)

    Recruiting
    • Renal Cell Carcinoma
    • Survey Questionnaire
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center
    Oct 19, 2022

    Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

    Completed
    • Platinum-Resistant Fallopian Tube Carcinoma
    • +8 more
    • Bevacizumab
    • Irinotecan Sucrosofate
    • Chicago, Illinois
      Northwestern University
    Dec 21, 2022

    Uveitis, Macular Edema, Vascular Endothelial Growth Factor Trial in Beijing (intravitreal injection of Conbercept)

    Terminated
    • Uveitis
    • +3 more
    • intravitreal injection of Conbercept
    • Beijing, Beijing, China
      Peking Union Medical College Hospital (PUMCH)
    Oct 24, 2022

    SCLC, Extensive Stage Trial in Shanghai (AK112, Etoposide, Carboplatin)

    Recruiting
    • SCLC, Extensive Stage
    • Shanghai, Shanghai, China
      Shun Lu
    Oct 12, 2022

    Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment Trial in Monastir (Bevacizumab Injection

    Recruiting
    • Proliferative Diabetic Retinopathy
    • +2 more
    • Bevacizumab Injection [Avastin]
    • Peripheral Retinal Cryoapplication
    • Monastir, Tunisia
      Fattouma Bourguiba University Hospital - Ophthalmology Departmen
    Aug 22, 2022

    Pheochromocytoma, Paraganglioma Trial in New York (Axitinib)

    Recruiting
    • Pheochromocytoma
    • Paraganglioma
    • New York, New York
      Columbia University Irving Medical Center
    Oct 5, 2022

    Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

    Not yet recruiting
    • Fallopian Tube Carcinosarcoma
    • +10 more
    • Bevacizumab
    • +4 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Dec 29, 2022

    Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

    Recruiting
    • Colorectal Cancer
    • Microsatellite Instability High
    • PD-1 inhibitor plus VEGF inhibitors
    • Guangzhou, Guangdong, China
      651 Dongfeng Road East
    May 27, 2022

    Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial

    Recruiting
    • Resectable Hepatocellular Carcinoma
    • +4 more
    • Atezolizumab
    • +2 more
    • Houston, Texas
    • +1 more
    Oct 12, 2022

    Proliferative Diabetic Retinopathy Trial in Beijing (proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use)

    Recruiting
    • Proliferative Diabetic Retinopathy
    • proactive Anti-VEGF (conbercept) use
    • passive Anti-VEGF (conbercept) use
    • Beijing, Beijing, China
      Peking University Third Hospital
    Dec 13, 2022

    Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,

    Recruiting
    • Recurrent Fallopian Tube Carcinoma
    • +2 more
    • Bevacizumab
    • +4 more
    • Phoenix, Arizona
    • +2 more
    Jun 27, 2022

    Neovascular Age-related Macular Degeneration Trial in United States (CLS-AX, Anti-VEGF)

    Completed
    • Neovascular Age-related Macular Degeneration
    • Phoenix, Arizona
    • +10 more
    Dec 1, 2022

    s in Wet AMD in Active Smokers

    Completed
    • Wet Age-related Macular Degeneration
    • Medical Data extraction
    • Brussels, Belgium
      CHU Brugmann
    Mar 7, 2022

    Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)

    Not yet recruiting
    • Ovarian Cancer
    • Houston, Texas
      MD Anderson Cancer Center
    Oct 9, 2023